28 May 2025 | 5:42AM EDT GS SUSTAIN: APAC Monitor A closer look at APAC fund performance and impact on flows While overall Sustainable fund performance has been challenging in APAC and globally, we have seen a dichotomy in performance between Sustainable funds with broader APAC regional mandates — which have outperformed non-ESG peers for six consecutive quarters — and Sustainable funds with individual country mandates. APAC funds that have outperformed saw inflows over the last year, and we continue to bel ...

Niagara Falls, NY, May 29, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leader in molecular imaging systems and services, is pleased to announce the sale of its NeuSight PET-CT 64-slice scanner to a prominent nuclear cardiologist specializing in advanced cardiovascular diagnostics and interventional care. This latest sale highlights the growing demand for Positron’s PET and PET-CT solutions, which combine cutting-edge technology with comprehensive clinical, tech ...

WEST CHESTER, Ohio, May 29, 2025 (GLOBE NEWSWIRE) -- AeroFlexx, a leader in sustainable packaging, has received Critical Guidance Recognition for recyclability from the Association of Plastic Recyclers (APR) for its proprietary mono-material AeroFlexx Pak. APR's Critical Guidance Recognition is one of the most widely accepted benchmarks for evaluating plastic packaging and provides independent validation and credibility that the AeroFlexx Pak is designed for recyclability. Under the APR Design® Recognition ...

Core Insights - Context Therapeutics Inc. has appointed Dr. Karen Chagin as Chief Medical Officer, effective June 9, 2025, succeeding Dr. Karen Smith who will remain on the Board of Directors [1][4] - Dr. Chagin has over a decade of experience in clinical development and regulatory strategy for T cell therapies, having previously held senior roles at Adaptimmune and Tmunity [2][3] - The company is focused on advancing T cell engaging bispecific antibodies for solid tumors, with a portfolio that includes CTIM-76, CT-95, and CT-202 [7] Leadership Transition - Dr. Chagin's appointment is seen as pivotal for the company's growth, bringing valuable insights from her experience in moving programs from early development to approval [4] - Dr. Smith's interim leadership has been acknowledged, highlighting her contributions during the transition [4] Stock Option Grant - As part of her employment, Dr. Chagin will receive a non-qualified stock option award of 153,000 shares, with the exercise price based on the closing price of the company's stock on her start date [5][6] - The stock option will vest over four years, with 25% vesting on the first anniversary and the remainder in equal monthly installments [6] Company Overview - Context Therapeutics is a biopharmaceutical company headquartered in Philadelphia, specializing in T cell engaging bispecific antibodies for solid tumors [7]

Core Viewpoint - Vermilion Energy Inc. has announced the divestment of its Saskatchewan and Manitoba assets for $415 million in cash, aiming to strengthen its balance sheet and improve financial position through debt repayment and deleveraging processes [1] Asset Overview: Production, Reserves and Liabilities - The divested assets produce approximately 10,500 barrels of oil equivalent per day (boe/d) and are expected to yield about $110 million of annual net operating income at current strip commodity prices [2] - The assets include Proved Developed Producing reserves of approximately 30 million boe and have undiscounted future abandonment liabilities worth $250 million [3] Revised 2025 Outlook - Following the asset sale, Vermilion expects its full-year average daily production to be in the range of 120,000-125,000 boe, with capital expenditures projected between $680 million and $710 million, reflecting a $50 million reduction due to the divestment [4] - The company plans to focus on increasing free cash flow rather than growing production in 2025 and 2026, amid extreme volatility in the energy market [4]

StealthGas (GASS) Q1 2025 Earnings Call May 28, 2025 10:00 AM ET Company Participants Michael Jolliffe - Chair of the BoardKonstantinos Sistovaris - Interim CFOHarry Vafias - President, CEO & Director Operator Good day, and thank you for standing by. Welcome to the StealthGas First Quarter twenty twenty five Results Conference Call and Webcast. At this time, all participants are in listen only mode. Please be advised that today's conference is being recorded. I would now like to hand the conference over to ...

StealthGas (GASS) Q1 2025 Earnings Call May 28, 2025 10:00 AM ET Company Participants Michael Jolliffe - Chair of the BoardKonstantinos Sistovaris - Interim CFOHarry Vafias - President, CEO & Director Operator Good day, and thank you for standing by. Welcome to the StealthGas First Quarter twenty twenty five Results Conference Call and Webcast. At this time, all participants are in listen only mode. Please be advised that today's conference is being recorded. I would now like to hand the conference over to ...

Ashford Hospitality Trust, Inc. (AHT) has taken another step in its strategic plan to deleverage and optimize its portfolio. The Dallas, TX-based REIT announced a definitive agreement to sell the 242-room Hilton Houston NASA Clear Lake in Houston, TX, for $27 million. The transaction, subject to closing conditions, is expected to be completed in June 2025.The sale represents an attractive exit for Ashford, yielding a capitalization rate of 3.2% on net operating income (NOI) or 23.6X Hotel EBITDA after adjus ...

Core Insights - Spectral AI's DeepView System has demonstrated a 95.3% overall accuracy in predicting burn healing potential, significantly outperforming traditional subjective assessments [1][2] - The technology has been recognized in the journal Burns, highlighting its clinical importance and transformative role in burn care [2] Company Overview - Spectral AI, Inc. is a Dallas-based predictive AI company focused on enhancing medical diagnostics for wound care, particularly for burn patients [3] - The DeepView System aims to provide objective and immediate assessments of burn wounds, facilitating faster and more accurate treatment decisions [3] - The company is committed to improving patient outcomes and reducing healthcare costs through its innovative technology [3] Clinical Significance - The study published in Burns represents the first multi-center evaluation of AI-enhanced multispectral imaging in burn assessment, showcasing the effectiveness of the DeepView System across various clinical settings [2] - The technology empowers clinicians with data-driven insights, improving decision-making regarding healing time and the need for surgical interventions [2] Industry Context - Burns is a prominent peer-reviewed medical journal dedicated to advancements in burn care and wound healing, serving as a critical platform for sharing innovative techniques and best practices [2]

Group 1 - Huhtamaki has appointed Axel Glade as President of the Flexible Packaging segment, effective July 1, 2025, earlier than previously announced [1] - Axel Glade will report to Ralf K. Wunderlich, the President & CEO, and will be based in Espoo, Finland [1] - Glade joins Huhtamaki from Constantia Flexibles, where he served as Executive Vice President of the Film Division [1] Group 2 - The Global Executive Team will include Ralf K. Wunderlich (Chair), Fredrik Davidsson, Sara Engber, Thomas Geust, Axel Glade, Ann O'Hara, Sami Pauni, Johan Rabe, Ingolf Thom, and Changsheng Wu [2] - Huhtamaki is a leading global provider of sustainable packaging solutions, focusing on hygiene, safety, accessibility, affordability, and food waste prevention [3] - The company has over 100 years of history, operates in 36 countries with around 18,000 professionals, and reported net sales of EUR 4.1 billion in 2024 [4]